Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 10
Submit an article Journal homepage
32
Views
11
CrossRef citations to date
0
Altmetric
Research Article

A Pilot Study on Feasibility and Efficacy of Amifostine Preceding High-dose Melphalan with Autologous Stem Cell Support in Myeloma Patients

E. Jantunen Department of Medicine, Kuopio University Hospital, P.O. Box 1777, 70211 Kuopio, Finland
,
T. Kuittinen Department of Medicine, Kuopio University Hospital, P.O. Box 1777, 70211 Kuopio, Finland
&
T. Nousiainen Department of Medicine, Kuopio University Hospital, P.O. Box 1777, 70211 Kuopio, Finland
Pages 1961-1965 | Published online: 03 Aug 2009

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Suzanne R Hayman & Shaji K Kumar. (2006) High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Review of Anticancer Therapy 6:3, pages 343-360.
Read now

Articles from other publishers (10)

June Eilers, Debra Harris, Karen Henry & Lee Ann Johnson. (2014) Evidence-Based Interventions for Cancer Treatment-Related Mucositis: Putting Evidence Into Practice. Clinical Journal of Oncology Nursing 18:s6, pages 80-96.
Crossref
Ourania Nicolatou-Galitis, Triantafyllia Sarri, Joanne Bowen, Mario Di Palma, Vassilios E. Kouloulias, Pasquale Niscola, Dorothea Riesenbeck, Monique Stokman, Wim Tissing, Eric Yeoh, Sharon Elad & Rajesh V. Lalla. (2012) Systematic review of amifostine for the management of oral mucositis in cancer patients. Supportive Care in Cancer 21:1, pages 357-364.
Crossref
Gordon L. PhillipsIIII, Steven H. Bernstein, Jane L. Liesveld, Camille N. Abboud, Michael W. Becker, Louis S. Constine, J.J. Ifthikharuddin, John E. Loughner, Laurie A. Milner, David H. Vesole & Jonathan W. Friedberg. (2011) A Phase I Trial: Dose Escalation of Melphalan in the “BEAM” Regimen Using Amifostine Cytoprotection. Biology of Blood and Marrow Transplantation 17:7, pages 1033-1042.
Crossref
M L Grazziutti, L Dong, M H Miceli, S G Krishna, E Kiwan, N Syed, A Fassas, F van Rhee, H Klaus, B Barlogie & E J Anaissie. (2006) Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplantation 38:7, pages 501-506.
Crossref
Rene-Jean Bensadoun, Mark M. Schubert, Rajesh V. Lalla & Dorothy Keefe. (2006) Amifostine in the management of radiation-induced and chemo-induced mucositis. Supportive Care in Cancer 14:6, pages 566-572.
Crossref
E Jantunen, T Kuittinen, K Penttilä, P Lehtonen, E Mahlamäki & T Nousiainen. (2006) High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplantation 37:10, pages 917-922.
Crossref
A Spencer, N Horvath, J Gibson, H M Prince, R Herrmann, J Bashford, D Joske, A Grigg, J McKendrick, I Prosser, R Lowenthal, S Deveridge & K Taylor. (2005) Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation 35:10, pages 971-977.
Crossref
G.L Phillips, B Meisenberg, D.E Reece, V.R Adams, A Badros, J Brunner, R Fenton, J Filicko, D Grosso, G.A Hale, D.S Howard, V.P Johnson, A Kniska, K.W Marshall, R Nath, E Reed, A.P Rapoport, N Takebe, D.H Vesole, J.L Wagner & N Flomenberg. (2004) Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study. Biology of Blood and Marrow Transplantation 10:7, pages 473-483.
Crossref
G L Phillips, B R Meisenberg, D E Reece, V R Adams, A Z Badros, J L Brunner, R G Fenton, J Filicko, D L Grosso, G A Hale, D S Howard, V P Johnson, A Kniska, K W Marshall, B Mookerjee, R Nath, A P Rapoport, C Sarkodee-Adoo, N Takebe, D H Vesole, J L Wagner & N Flomenberg. (2004) Activity of single-agent melphalan 220–300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplantation 33:8, pages 781-787.
Crossref
. (2003) Current Awareness in Hematological Oncology. Hematological Oncology 21:1, pages 43-50.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.